Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NMT1 | P30419 | 1/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1239240 | 0.89 | SIGMAR1 (0.57) | SIGMAR1KCNJ1 | |
| SCHEMBL25595690 | 0.88 | SIGMAR1 (0.55) | SIGMAR1KCNJ1LTA4H | |
| SCHEMBL2326201 | 0.85 | LTA4H (0.64) | SIGMAR1LTA4H | |
| SCHEMBL11149095 | 0.82 | SIGMAR1 (0.62) | SIGMAR1 | |
| SCHEMBL1509508 | 0.82 | SIGMAR1 (0.71) | SIGMAR1KCNJ1 | |
| SCHEMBL3593088 | 0.81 | SIGMAR1 (0.89) | SIGMAR1LTA4H | |
| SCHEMBL13858201 | 0.81 | SIGMAR1 (0.70) | SIGMAR1NMT1KCNJ1LTA4H | |
| SCHEMBL427230 | 0.81 | SIGMAR1 (0.70) | SIGMAR1 | |
| SCHEMBL2730391 | 0.81 | SIGMAR1 (0.57) | SIGMAR1KCNJ1 | |
| SCHEMBL578497 | 0.79 | LMNA (0.67) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092032-A1 | DEOXYCYTIDINE KINASE INHIBITORS | INSTITUT JEAN PAOLI & IRENE CALMETTES CENTRE REGIONAL DE LUTTE CONTRE LE CANCER (FR) | 2025-03-20 | — | — | US | disclosed |
| CN-110506044-B | BRD4 inhibitor and preparation and application thereof | 中国科学院上海药物研究所 | 2022-07-05 | — | — | CN | disclosed |
| CN-110506044-A | A kind of BRD4 inhibitor and its preparation and application | SHANGHAI INST MATERIA MEDICA CAS | 2019-11-26 | — | — | CN | disclosed |
| CN-108727380-A | A kind of BRD4 inhibitor and its preparation and application | 中国科学院上海药物研究所 | 2018-11-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092032-A1 | DEOXYCYTIDINE KINASE INHIBITORS | DCK, DTYMK, TYMP | SIGMAR1 3889/4885RAB9A 2529/4885NMT1 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.